Celldex Therapeutics Prices $300 Million Public Offering, Significant Dilution Expected

summarizeSummary

Celldex Therapeutics announced the pricing of its underwritten public offering, raising approximately $300 million by selling 10.345 million shares at $29.00 each, with an option for additional shares, leading to substantial potential dilution.

check_boxKey Events

• Offering Priced

  Celldex priced its underwritten public offering of 10,345,000 shares of common stock at $29.00 per share, finalizing the terms of the offering initiated on April 1, 2026.

• Significant Capital Raise

  The offering is expected to generate approximately $282 million in net proceeds for the company, after deducting underwriting discounts and commissions and other estimated offering expenses.

• Underwriters' Option for Additional Shares

  Underwriters have a 30-day option to purchase up to an additional 1,551,750 shares of common stock, which could increase the total gross proceeds to approximately $345 million.

• Use of Proceeds

  Funds will support ongoing commercial readiness activities and the commercial launch of barzolvolimab, clinical and preclinical development of product candidates, growth of the bispecific antibody platform, and general corporate purposes.

auto_awesomeAnalysis

This 8-K filing finalizes the terms of the public offering previously announced on April 1, 2026, setting the price at $29.00 per share. The company will issue 10.345 million shares, with underwriters having a 30-day option to purchase an additional 1.551 million shares. If the option is fully exercised, the offering could total 11.896 million shares, representing a significant capital raise of approximately $345 million (gross, if option exercised). While the capital infusion of approximately $282 million (net) is intended to fund commercial readiness for barzolvolimab, clinical development, and general corporate purposes, the offering introduces substantial dilution for existing shareholders.